Genomines | $45,000,000 | (Sep 18, 2025)
Synthesize Bio | $10,000,000 | (Sep 18, 2025)
Moby | $5,000,000 | (Sep 18, 2025)
Certified by Founder
Lodge
LoQus23 Therapeutics Ltd
start up
United Kingdom
- Cambridge, Cambridgeshire
- 02/10/2024
- Series A
- $46,550,175
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
- Industry Biotechnology Research
- Website https://loqus23.com/
- LinkedIn https://www.linkedin.com/company/loqus23-therapeutics-ltd/
Invisible Technologies | $100,000,000 | (Sep 18, 2025)
Mueon Corporation | $15,500,000 | (Sep 18, 2025)
Stablecore | $20,000,000 | (Sep 18, 2025)
Envive AI | $15,000,000 | (Sep 18, 2025)
Markup AI | $27,500,000 | (Sep 18, 2025)
Turnout | $21,000,000 | (Sep 18, 2025)
GridStrong | $10,000,000 | (Sep 18, 2025)
Imagine Pediatrics | $67,000,000 | (Sep 18, 2025)
Rec Technologies | $11,000,000 | (Sep 18, 2025)